Early Conversion of Intensive Insulin Therapy to IDegLira Demonstrates Higher Efficacy and Safety in Reducing Fasting Blood Glucose and HbA1c in T2DM Patients

Abstract

Caiyun Guo, Yang Lu Department of Endocrinology, YuYao People’s Hospital, Ningbo, Zhejiang Province, People’s Republic of ChinaCorrespondence: Caiyun Guo, Department of Endocrinology, YuYao People’s Hospital, 800 Chengdong Road, Ningbo, Zhejiang Province, 315400, People’s Republic of China, Email [email protected]: A short-term insulin intensive therapy is an important method used in clinical practice to control blood glucose, and a scientific post-treatment plan is key to long-term blood glucose stability control. This study aimed to investigate efficacy and safety of early conversion of intensive insulin therapy to IDegLira in T2DM patients.Methods: This study was a prospective study, involving 80 T2DM patients finally. Patients were firstly treated with insulin for intensified therapy (Pre-IDegLira group), then switched to insulin degludec and liraglutide (IDegLira) for 3 months (IDegLira-3 months group). Data including HbA1c, fasting blood glucose, fasting C-peptide, weight, insulin dosage, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were analyzed. Correlations between fasting blood glucose and other parameters were evaluated with Pearson correlation analysis.Results: IDegLira early conversion significantly reduced fasting blood glucose (p< 0.001), weight (p=0.015), and insulin dosage (p=0.001) of T2DM patients compared to those of Pre-IDegLira group. HbA1c level was remarkably lower in T2DM patients underwent IDegLira early conversion compared to that in Pre-IDegLira group (p< 0.001), with HbA1c < 7% proportion of 73.75% (59/80). IDegLira early conversion significantly downregulated levels of TC (p< 0.001), TG (p< 0.001), LDL-C (p< 0.001), and upregulated HDL-C level (p=0.017) of T2DM patients, compared to those in Pre-IDegLira group. IDegLira early conversion markedly reduced ALT (p< 0.001) and AST (p=0.002) levels of T2DM patients compared to those in Pre-IDegLira group. IDegLira early conversion demonstrated a positive correlation between fasting blood glucose and HbA1c (r=0.531, p< 0.001) or TG level (r=0.336, p=0.002) in T2DM patients.Conclusion: Early conversion of intensive insulin therapy to IDegLira effectively reduced fasting blood glucose and HbA1c in T2DM patients with higher safety.Keywords: insulin intensive therapy, IDegLira, T2DM, early conversion, safety

Keywords

• insulin intensive therapy
• ideglira
• t2dm
• early conversion
• safety